Treatment of Charcot-Marie-Tooth neuropathies

Area of Science:

• Neurology
• Genetics
• Molecular Biology

Background:

• Charcot-Marie-Tooth (CMT) encompasses diverse inherited peripheral neuropathies causing progressive disability.
• Current management focuses on supportive care, including rehabilitation and symptom management, as effective therapies are lacking.

Purpose of the Study:

• To review recent advancements in understanding CMT pathophysiology.
• To explore emerging therapeutic strategies targeting genetic and molecular pathways for CMT.

Main Methods:

• Literature review of genetic mutations, disease mechanisms, and potential therapeutic targets in CMT.
• Analysis of progress in gene silencing (e.g., PMP22 in CMT1A) and gene expression (e.g., GJB1 in CMT1X).

Main Results:

• Significant progress in identifying CMT-associated mutations and understanding disease pathways over the last three decades.
• Identification of promising therapeutic targets, including NRG-1 axis inhibitors, UPR modulators, and HDAC enzyme family modulators.

Conclusions:

• Genetic and molecular approaches show promise for developing novel therapeutic strategies for various CMT types.
• Targeting specific genes and pathways represents a key future direction for effective CMT treatment.